Drug/Small Molecule:
docetaxel

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


FDA Label for docetaxel

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Breast Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Carcinoma, Non-Small-Cell Lung
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Head and Neck Neoplasms
    • Indications & usage section, Adverse reactions section
    • source: PHONT
  • Leukopenia
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Lung Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Prostatic Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Stomach Neoplasms
    • Warnings section, Adverse reactions section
    • source: PHONT

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2A6 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *4A N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1042858 2232G>A, 4099466G>A, 4159466G>A, 48543G>A, Ala744=, RRM1:2464G>A, rs1042858
G > A
Synonymous
Ala744Ala
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available CA VA
rs1048943 1384A>C, 1384A>G, 1384A>T, 3103T>A, 3103T>C, 3103T>G, 45803542T>A, 45803542T>C, 45803542T>G, 75012985T>A, 75012985T>C, 75012985T>G, CYP1A1*2C, CYP1A1:2455A>G, CYP1A1:4889A>G, CYP1A1:Hinc II, CYP1A1:I462V, CYP1A1:m2, Ile462Leu, Ile462Phe, Ile462Val
T > G
T > A
T > C
Missense
Ile462Phe
Ile462Val
Ile462Leu
No VIP available CA VA
rs1056836 10122C>C, 1294C>C, 17120090C>G, 38298203C>G, CYP1B1*3, CYP1B1: L432V, CYP1B1:4326 C>G, CYP1B1:L432V, Leu432=
G > C
Not Available
No VIP available CA VA
rs11045585 13805818A>G, 1683-5676A>G, 21045694A>G, 87057A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs11615 18191871A>G, 354T>C, 45923653A>G, 63434T>C, Asn118=, ERCC1:19007T>C, ERCC1:Asn118Asn
A > G
Synonymous
Asn118Asn
No VIP available No Clinical Annotations available VA
rs11710163 -27+9024T>C, 12636288A>G, 12696288A>G, 14391T>C
A > G
Intronic
No VIP available CA No Variant Annotations available
rs121434568 177791T>G, 2573T>G, 55181822T>G, 55191822T>G, Leu858Arg
T > G
Not Available
Leu858Arg
No VIP available CA VA
rs12415607 -1310C>A, -1534C>A, -1542C>A, -1608C>A, -905C>A, 115438204C>A, 66242668C>A
C > A
5' Flanking
No VIP available CA VA
rs12418 *4785G>A, 24577478G>A, 53895G>A, 73773014G>A, CHST3:rs12418 A>G, NM_004273.3:c.*4785G>A
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs12762549 101620771C>G, 52425235C>G
C > G
Not Available
No VIP available CA VA
rs12960 1180945G>A, 2063G>A, 50524G>A, 89620328G>A, Arg688Gln, NM_003119.2:c.2063G>A, NP_003110.1:p.Arg688Gln, SPG7:rs12960 A>G
G > A
Missense
Arg688Gln
No VIP available No Clinical Annotations available VA
rs13181 *304T>G, 18123137T>G, 2251A>C, 23927A>C, 45854919T>G, ERCC2 Lys751Gln, ERCC2:2251A>C, ERCC2:Lys751Gln, Lys751Gln, rs13181:T>G
T > G
Missense
Lys751Gln
No VIP available CA VA
rs1382368 316-40514C>T, 33045434C>T, 82451075C>T
C > T
Intronic
No VIP available CA VA
rs139887 14144C>G, 17761965G>C, 38371396G>C, 698-1191C>G
G > C
Intronic
No VIP available CA VA
rs1402467 108994808C>G, 13668637C>G, 15C>G, Asp5Glu, NM_006588.2:c.15C>G, NP_006579.2:p.Asp5Glu, SULT1C2:rs1402467 C>G
C > G
Missense
Asp5Glu
No VIP available No Clinical Annotations available VA
rs16886403 33347T>C, 483-13181T>C, 56139246T>C, 6733605T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs1695 12658484A>G, 313A>G, 6624A>G, 67352689A>G, GSTP1*2, GSTP1*B, GSTP1: I105V, GSTP1:A313G, GSTP1:I105V, GSTP1:Ile105Val, Ile105Val, Part of haplotypes GSTP1*B and GSTP1*C, rs1695:A>G
A > G
Missense
Ile105Val
No VIP available No Clinical Annotations available VA
rs17309872 *771A>T, *843T>A, 32814T>A, 33515788A>T, 3711880A>T, 58044A>T
A > T
3' Flanking
No VIP available No Clinical Annotations available VA
rs17661089 56105996A>G, 6700355A>G, 97A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs1799793 11587G>A, 18135477C>T, 45867259C>T, 862G>A, 934G>A, Asp288Asn, Asp312Asn, XPD Asp312Asn, XPD:Asp312Asn
C > T
Missense
Asp288Asn
rs1799931 14616G>A, 18258370G>A, 6116516G>A, 857G>A, NAT2:857G>A, NAT2:GLY286GLU, NAT2:rs1799931 A>G, NM_000015.2:c.857G>A, NP_000006.2:p.Gly286Glu, included in NAT2*7B. A allele defines "M3", signature SNP for NAT2*7 allelic group
G > A
Missense
Gly286Glu
No VIP available No Clinical Annotations available VA
rs1800440 10186A>G, 1358A>G, 17120026T>C, 38298139T>C, Asn453Ser
T > C
Missense
Asn453Ser
No VIP available No Clinical Annotations available VA
rs1801133 11856378G>A, 14783C>T, 665C>T, 677C>T, 7861110G>A, A222V, Ala222Val, C677T, MTHFR: c.677C>T, MTHFR:667C>T, p.A222V
G > A
Missense
Ala222Val
No VIP available No Clinical Annotations available VA
rs1805087 237048500A>G, 2756A>G, 30566279A>G, 94920A>G, Asp919Gly, MS 2756A>G, MS D919G, MTR:2756A>G, MTR:Asp919Gly
A > G
Missense
Asp919Gly
No VIP available CA VA
rs1871450 *3785G>A, 24576478G>A, 52895G>A, 73772014G>A, CHST3:rs1871450 A>G, NM_004273.3:c.*3785G>A
G > A
3' UTR
No VIP available CA VA
rs1883322 -101-8958C>T, -102+4436C>T, 14-18098C>T, 35309806C>T, 35369806C>T, 64472C>T, PPARD:rs1883322 A>G
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs1937840 128781C>G, 448-212C>G, 5081307C>G, 5141307C>G
C > G
Intronic
No VIP available CA VA
rs2016520 -87C>T, 14-9126C>T, 35318778C>T, 35378778C>T, 73444C>T, NM_006238.3:c.-87C>T, PPARD:rs2016520 A>G
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs2072671 20915701A>C, 7595789A>C, 79A>C, CDA: c.79A>C, CDA:79A>C, K27Q, Lys27Gln, p.Lys27Gln
A > C
Missense
Lys27Gln
No VIP available CA VA
rs2227291 107309G>C, 2299G>C, 564810G>C, 77268502G>C, ATP7A:rs2227291 C>G, NM_000052.4:c.2299G>C, NP_000043.3:p.Val767Leu, Val767Leu
G > C
Missense
Val767Leu
No VIP available CA VA
rs2227310 1020C>G, 115489152C>G, 66293616C>G, 690C>G, 731C>G, 765C>G, 864C>G, Asp230Glu, Asp255Glu, Asp288Glu, Asp340Glu, Thr244Ser
C > G
Missense
Asp230Glu
Asp230Ser
No VIP available CA VA
rs2234922 19544185A>G, 226026406A>G, 33610A>G, 416A>G, EPHX1: H139R, His139Arg, NM_000120.2: c.416A>G, NT_004559.13: g.2228559A>G, mRNA 457A>G, mRNA 691A>G, p.His139Arg
A > G
Missense
His139Arg
No VIP available CA VA
rs2238472 16191599C>T, 16251599C>T, 3803G>A, 70730G>A, ABCC6:rs2238472 A>G, Arg1268Gln, NM_001171.5:c.3803G>A, NP_001162.4:p.Arg1268Gln
C > T
Missense
Arg1268Gln
No VIP available CA VA
rs2292954 1173740A>G, 1507A>G, 43319A>G, 89613123A>G, NM_003119.2:c.1507A>G, NP_003110.1:p.Thr503Ala, SPG7:rs2292954 C>T, Thr503Ala
A > G
Missense
Thr503Ala
No VIP available CA VA
rs2301159 *755C>T, 103697728G>A, 16787404G>A, 26469C>T, NM_000452.2:c.*755C>T, SLC10A2:rs2301159 C>T
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs25487 1196A>G, 16323944T>C, 44055726T>C, Gln399Arg, XRCC1 Arg399Gln, XRCC1:Arg399Gln
T > C
Missense
Gln399Arg
No VIP available CA VA
rs2740574 -392G>A, 37414939C>T, 4713G>A, 5'-flanking region -392A>G, 99382096C>T, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs2762939 14266C>G, 22977343G>C, 52781251G>C, 733-149C>G
G > C
Intronic
No VIP available CA VA
rs2849380 12254G>A, 585+5955G>A, 60979360C>T, 8770224C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs34743033 28-bp tandem repeats, CCGCGCCACTTGGCCTGCCTCCGTCCCG, TSER*2, TSER*3, TYMS: 28 bp tandem repeat, TYMS: 2R, TYMS: TSER *2/*3, TYMS:TSER 28-basepair 5'UTR enhancer region repeat
CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC > 4
CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC > 3
CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC > (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2
Not Available
No VIP available CA VA
rs3734254 *1154C>T, 35335010C>T, 35395010C>T, 89676C>T, PPARD:rs3734254 C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs3787554 12837C>T, 22978772G>A, 52782680G>A, 641-308C>T
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs3834935 *347_*348insA, 110891_110892insA, 13829652_13829653insA, 21069528_21069529insA
- > A
3' UTR
No VIP available CA VA
rs4148943 *1278C>T, 24573971C>T, 50388C>T, 73769507C>T, CHST3:rs4148943 C>T, NM_004273.3:c.*1278C>T
C > T
3' UTR
No VIP available CA VA
rs4148945 *1361C>T, 24574054C>T, 50471C>T, 73769590C>T, CHST3:rs4148945 C>T, NM_004273.3:c.*1361C>T
C > T
3' UTR
No VIP available CA VA
rs4148947 *1888T>C, 24574581T>C, 50998T>C, 73770117T>C, CHST3:rs4148947 C>T, NM_004273.3:c.*1888T>C
T > C
3' UTR
No VIP available CA VA
rs4148950 *3477G>A, 24576170G>A, 52587G>A, 73771706G>A, CHST3:rs4148950 A>G, NM_004273.3:c.*3477G>A
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs4149118 13771705G>A, 21011581G>A, 359+76G>A, 52944G>A
G > A
Intronic
No VIP available CA VA
rs4353229 *290T>C, *406T>C, 115489589T>C, 66294053T>C
T > C
3' UTR
No VIP available CA VA
rs4646487 17251093C>T, 19506C>T, 47279175C>T, 517C>T, Arg173Trp, CYP4B1:rs4646487 C>T, NM_000779.3:c.517C>T, NP_000770.2:p.Arg173Trp
C > T
Missense
Arg173Trp
No VIP available CA VA
rs518329 14592T>C, 21576998T>C, 23695236T>C, 476+2013T>C
T > C
Intronic
No VIP available CA VA
rs544093 1164+44886G>T, 130858G>T, 154457493G>T, 58626950G>T
G > T
Intronic
No VIP available CA VA
rs6922548 -101-25241A>G, -197-11752A>G, 14-34381A>G, 35293523A>G, 35353523A>G, 48189A>G, PPARD:rs6922548 A>G
A > G
Intronic
No VIP available CA VA
rs726501 21967G>A, 482+15984G>A, 56127866G>A, 6722225G>A
G > A
Intronic
No VIP available CA VA
rs730720 *4533C>T, 24577226C>T, 53643C>T, 73772762C>T, CHST3:rs730720 A>G, NM_004273.3:c.*4533C>T
C > T
3' UTR
No VIP available CA VA
rs7311358 13775884G>A, 21015760G>A, 57123G>A, 699G>A, Met233Ile, SCLO1B3: exon 7 c.699G>A, mRNA 825G>A, p.Met233Ile
G > A
Missense
Met233Ile
VIP No Clinical Annotations available No Variant Annotations available
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
No VIP available CA VA
rs7769719 -101-16239G>A, -197-2750G>A, 14-25379G>A, 35302525G>A, 35362525G>A, 57191G>A, PPARD:rs7769719 A>G
G > A
Intronic
No VIP available CA VA
rs7921977 -1+461C>T, -169C>T, -177C>T, -243C>T, 115439569C>T, 56C>T, 66244033C>T, Thr19Ile
C > T
Missense
Thr19Ile
No VIP available CA VA
rs861539 104165753G>A, 1651-1239G>A, 1782-1239G>A, 21071C>T, 722C>T, 75229G>A, 85165753G>A, Thr241Met
G > A
Intronic
Thr241Met
No VIP available CA VA
rs870995 -76-3532C>A, 178913006C>A, 51696C>A, 85408152C>A
C > A
Intronic
No VIP available CA VA
rs879207 3069970A>G, 3466596A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs9937 2223A>G, 4099457A>G, 4159457A>G, 48534A>G, RRM1:2455A>G, Thr741=, rs3177016
A > G
Synonymous
Thr741Thr
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Docetaxel anhydrous
  • Docetaxel, Trihydrate
  • TXL
  • docetaxel
Trade Names
  • Taxotere
Brand Mixture Names

PharmGKB Accession Id:
PA449383

Description

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules.

Source: Drug Bank

Indication

For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Lastly, for use, in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the beta-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

Source: Drug Bank

Pharmacology

Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).

Source: Drug Bank

Protein Binding

About 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins.

Source: Drug Bank

Half-Life

Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. Alpha (distribution) 4 minutes. Beta 36 minutes. Gamma (terminal) 11.1 hours.

Source: Drug Bank

Toxicity

Oral LD 50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m 2 and the other received 200 mg/m 2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

Source: Drug Bank

Clearance

Route of Elimination

Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.

Source: Drug Bank

Volume of Distribution

  • 113 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C43H53NO14

Source: Drug Bank

Isomeric SMILES

CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)OC(C)(C)C)O)O)OC(=O)c6ccccc6)(CO4)OC(=O)C)O)C)O

Source: OpenEye

Canonical SMILES

CC(=O)O[C@@]12CO[C@@H]

Source: Drug Bank

Average Molecular Weight

807.8792

Source: Drug Bank

Monoisotopic Molecular Weight

807.346605409

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Taxane Pathway, Pharmacokinetics
    Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
BCL2 (source: Drug Bank)
TUBB1 (source: Drug Bank)

Drug Interactions

Drug Description
docetaxel Aprepitant may change levels of the chemotherapy agent, docetaxel. (source: Drug Bank)
aprepitant Aprepitant may change levels of the chemotherapy agent, docetaxel. (source: Drug Bank)
erythromycin The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
erythromycin Erythromycin may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
josamycin Josamycin may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
ketoconazole The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
midazolam The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
midazolam Midazolam may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
orphenadrine The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
orphenadrine Orphenadrine may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
quinupristin This combination presents an increased risk of toxicity. (source: Drug Bank)
testosterone The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
testosterone Testosterone propionate may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Erythromycin may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Ketoconazole may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Midazolam may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Orphenadrine may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel This combination presents an increased risk of toxicity (source: Drug Bank)
docetaxel Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Testosterone may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
docetaxel Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank)
docetaxel The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects. (source: Drug Bank)
docetaxel Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to docetaxel: 99

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990). 2014. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. McWhinney-Glass Sarah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. British journal of clinical pharmacology. 2013. Voon Pei Jye, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2013. Ramnath N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. Pharmacogenomics. 2013. Nogueira Augusto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenetics and genomics. 2012. Lewis Lionel D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. Chest. 2012. Qian Ji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012. Romero A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. Journal of cancer research and clinical oncology. 2012. Dong Ningning, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment. 2012. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The lancet oncology. 2012. Rosell Rafael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic approach towards personalized anticancer drug therapy. Pharmacogenomics. 2012. Midorikawa Yutaka, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011. Giovannetti Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of SLCO1B3 Haplotype-tag SNPs on Docetaxel Disposition in Chinese Nasopharyngeal Cancer Patients. British journal of clinical pharmacology. 2011. Chew Sin-Chi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics. 2011. Peters Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The lancet oncology. 2011. Zhou Caicun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Li Yafei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of polymorphisms in MTHFR 677 C¿T, TYMS 3R¿2R and MTR 2756 A¿G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics. 2011. Cui Lian-Hua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer chemotherapy and pharmacology. 2010. Harmsen Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung cancer (Amsterdam, Netherlands). 2010. Carcereny Enric, et al. PubMed
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. The pharmacogenomics journal. 2010. Deeken J F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Douillard Jean-Yves, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The lancet oncology. 2010. Mitsudomi Tetsuya, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxane Pathway. Pharmacogenetics and genomics. 2009. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenetics and genomics. 2009. Lee Soo-Chin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Current clinical pharmacology. 2009. Srinivas Nuggehally R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 2009. Kong Sun-Young, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecologic oncology. 2009. Kim Hee Seung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America. 2009. Swanton Charles, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic pathway analysis of docetaxel elimination. Clinical pharmacology and therapeutics. 2009. Baker S D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology. 2008. Font Albert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
RPN2 gene confers docetaxel resistance in breast cancer. Nature medicine. 2008. Honma Kimi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP450 pharmacogenetics for personalizing cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2008. van Schaik Ron H N. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer science. 2008. Kiyotani Kazuma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxanes, microtubules and chemoresistant breast cancer. Biochimica et biophysica acta. 2008. McGrogan Barbara T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England journal of medicine. 2008. Sparano Joseph A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular cancer therapeutics. 2008. Sissung Tristan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. The New England journal of medicine. 2007. Posner Marshall R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. The New England journal of medicine. 2007. Vermorken Jan B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal. 2007. Marsh S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Archiv : an international journal of pathology. 2007. Materna Verena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic signatures to guide the use of chemotherapeutics. Nature medicine. 2006. Potti Anil, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Hahn Noah M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lagas Jurjen S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International journal of cancer. Journal international du cancer. 2005. Huisman Maarten T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Molecular endocrinology (Baltimore, Md.). 2005. Masuyama Hisashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeting microtubules for cancer chemotherapy. Current medicinal chemistry. Anti-cancer agents. 2005. Zhou Jun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clinical pharmacology and therapeutics. 2004. Engels Frederike K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Microtubules as a target for anticancer drugs. Nature reviews. Cancer. 2004. Jordan Mary Ann, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Preclinical pharmacology of the taxanes: implications of the differences. The oncologist. 2004. Gligorov Joseph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular cancer therapeutics. 2003. Brooks Tracy A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular cancer therapeutics. 2003. Fuino Lianne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Hasegawa Seiichi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharmaceutical research. 2003. Woo Jong Soo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. The Journal of clinical investigation. 2002. Fellner Stephan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. Goh Boon-Cher, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. International journal of cancer. Journal international du cancer. 2001. Egawa C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature medicine. 2001. Synold T W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer research. 2000. Allen J D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000. Verschraegen C F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of docetaxel. Clinical pharmacokinetics. 1999. Clarke S J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998. Valero V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998. Shou M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. International journal of cancer. Journal international du cancer. 1998. Su G M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug metabolism and disposition: the biological fate of chemicals. 1998. Monsarrat B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bcl2 is the guardian of microtubule integrity. Cancer research. 1997. Haldar S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variability in human cytochrome P450 paclitaxel metabolism. The Journal of pharmacology and experimental therapeutics. 1995. Sonnichsen D S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inactivation of Bcl-2 by phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 1995. Haldar S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995. Gianni L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taxanes: a new class of antitumor agents. Cancer investigation. 1995. Huizing M T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0075-8001-80
DrugBank:
DB01248
ChEBI:
4672
KEGG Compound:
C11231
PubChem Compound:
148124
PubChem Substance:
13410
46506766
Drugs Product Database (DPD):
2177080
ChemSpider:
130581
Therapeutic Targets Database:
DAP000590
FDA Drug Label at DailyMed:
82731db6-92fc-483b-9d73-9b2aed79b104

Clinical Trials

These are trials that mention docetaxel and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.